Background: NPM1 gene at chromosome 5q35 is involved in recurrent translocations in leukemia and lymphoma. It also undergoes mutations in 60% of adult acute myeloid leukemia (AML) cases with normal karyotype. The incidence and significance of NPM1 deletion in human leukemia have not been elucidated.
Introduction
In humans, nucleophosmin (NPM1) is implicated in the genesis of different cancers [1] . We previously found NPM1 exon 12 somatic mutations in approximately 60% of adult acute myeloid leukemia (AML) and normal karyotype [2] . NPM1 fusion proteins are also specifically involved: t(5;17)(q35;q21)/NPM1-RARA causes acute promyelocytic leukemia; t(2;5)(p23;q35)/NPM1-ALK underlies anaplastic large cell lymphoma; t(3;5)(q26;q35)/NPM1-MLF1 is associated with myelodysplastic syndromes (MDS) and AML with trilineage dysplasia and poor prognosis (http://AtlasGeneticsOncology.org). In the last cytogenetic subgroup of MDS/AML a cryptic loss of NPM1 gene may occur at the 5q35 breakpoint of the translocation [3] . Despite of this sporadic observation the role of NPM1 deletion in hematological malignancies remains to be elucidated. In human leukemia an interstitial isolated deletion at chromosome 5q identifies a myelodysplastic syndrome with a benign clinical course (the ''5q-syndrome'') [4] . Moreover a partial or complete 5q loss (5q-/-5) may occur as part of a complex karyotype in high risk MDS/AML, including cases arising after radio-and/or chemo-therapy [5] . Chromosomes 5q-are heterogeneous in size as deleted segments vary in extension and have different centromeric and telomeric breakpoints [6, 7] . Experimental evidences indicate that the 5q-syndrome originates from haploinsufficiency of more than one critical pathogenetic gene included in the hemizygous chromosome deletion [8] [9] [10] [11] [12] . Thus identification of genes that go lost in different 5q-chromosomes of MDS and AML is very important to understand the pathophysiology of the associated malignant disorders. Focusing on NPM1 gene we investigated a large series of MDS and AML with and without a 5q deletion.
Materials and Methods

Patient inclusion criteria
AML or MDS and one of the following abnormal karyotypes, according to the ISCN [13] : isolated 5q-; 5q-/-5 plus one or more additional changes (non-isolated); complex karyotypes without 5q-/-5. 145 patients (60 males; 85 females; age range 9-94 years; 71 with MDS and 74 with AML) were recruited from the Hematological Institutions, University of Perugia, Italy, Sant Pau Hospital, Barcelona, Spain, and the Demokritos Cancer Centre, Athens, Greece.
FISH
Protocols have already been described [14] . Commercial FISH probes were provided by Abbott/Vysis (Downers Grove, IL, USA): LSI EGR1/D5S721, D5S23 dual color probe; LSI CSF1R (5q33-q34) spectrum orange/D5S721, D5S23 spectrum green; LSI c-MYC dual color break apart rearrangement probe; LSI 13 (RB1) 13q14 spectrum orange probe. Caltech DNA clones CTC-286C20 (FGFR4/ 5q35.2), CTC-549A4 (NSD1/5q35.3), CTD-2131H15 (39CTNNA1/ 5q31), CTD-2324F6 (59CTNNA1/5q31), CTD-2342K5 (BRCA2/ 13q12), and CTD-3199J23 (BRCA1/17q21) were purchased from Invitrogen (Carlsbad, CA, USA). Other DNA clones were selected from the RPCI libraries (http://www.ncbi.nlm.gov/project/mapview, Build 37.1), provided by Mariano Rocchi, Department of Genetics and Microbiology, University of Bari, Italy and grown, labelled, and validated at the Cytogenetics and Molecular Genetics Laboratory, Hematology Department, University of Perugia, Italy. Clones mapping at 5q11.2-5q14.1 listed from centromere to telomere: RP11-266N13,  RP11-489L13, RP11-298P6, RP11-79C20, RP11-170N5, RP11-195G20, RP11-633M1, RP11-195E2, RP11-771B3, RP11-79P5,  RP5-910M8, RP11-229C3, RP11-469J18, RP11-996M9, RP11 -168A11, RP11-80K5, RP11-1089B2, and RP11-885P10. Genespecific RPCI clones: RP11-89G4 (IRF1/5q31), RP11-946D14 (RPS14/5q33), RP11-204L7 (39SPARC/5q33), RP11-642K17 (59SPARC/5q33), RP11-117L6 (NPM1/5q35.1), RP1-240G13 (5qter subtelomeric probe), RP11-480O8 (BUB1A/2q14), RP11-383G6 (39ATR/3q23), RP11-427D1 (59ATR/3q23), RP11-669K4 (FBW7/ 4q31), RP11-149I2 (CDKN2A/B/9p21), RP11-380G5 (PTEN/10q23), RP11-241D13 (ATM/11q22), RP11-880O16 (CHEK1/11q24), RP11-1137N1 (MDM2/12q15), RP11-248I17 (BUB1B/15q15), RP11-436C9 (39CHEK2/22q12), RP11-444G7 (59CHEK2/22q12).
NPM1 and TP53 Mutational Analysis
Exon 12 NPM1 mutations were studied by direct sequencing of PCR products from genomic DNA using the following primers: NPM1_ex12for 59-ATGTCTATGAAGTGTTGTGGTTCC-39 and NPM1_ex12rev 59-CAGGCATTTTGGACAACACA-39. TP53 gene (NC_000017.10, 7590863.7571720) mutations on exons 2-12 ( Table 1) were studied using PCR-based denaturing HPLC using a WAVE-MD TM System (Transgenomic, Omaha, NE) equipped with a DNASep Cartridge. PCR assays were performed in a volume of 25 ml, containing 100 ng of genomic DNA, 6 pmol of forward and reverse primer, 200 mM dNTPs, 0.3 U of AmpliTaq Gold (Life Technologies Corp., Carlsbad, CA, USA). Gradient elution and melting temperature conditions were established by Wave-Maker Navigator version 1.7 software (Transgenomic). Bidirectional sequencing was performed on samples with abnormal chromatographs using ABI prism 3130 (Life Technologies). Missense and frameshift mutations were detected using Finch TV version 1.4.0 and described according to CCDS 11118.1 (NM_0000546.4).
NPM1 expression by Real Time Quantitative PCR
RT-qPCR was performed on cryopreserved bone marrow RNA samples from 9 patients with NPM1+/-and 5q-, 10 patients with NPM1+/+ and 5q-, 5 patients with NPM1+/+ without 5q-and 11 healthy controls. Total RNA was extracted using Trizol (Invitrogen) according to the manufacturer's protocol with minor modifications. Two micrograms of total RNA were treated with 4 Units of Dnase I (Deoxyribonuclease I Amplification Grade, Sigma) in a total volume of 11 ml. One microgram of treated RNA was reverse transcribed to single strand cDNA according to the EAC protocol [15] and 1 mg was used in a control reaction (-RT) using the same procedure without the M-MLV reverse transcriptase enzyme (Perkin Elmer Applied Biosystems, Foster City, USA). The RT-qPCR mixture reaction contained 12.5 ml Taq Man Universal PCR Master Mix (Life Technologies), 300 nM primers, 200 nM probe and 5 ml cDNA (1/10 of RT product), in a total volume of 25 ml. Amplification conditions were: 2 minutes at 50uC, 10 minutes at 95uC followed by 40 cycles at 95uC for 15 seconds and at 60uC for 1 minute [16] . RT-qPCR reactions and fluorescence measurements were performed on an ABI PRISM 7700 Sequence Detection System (Life Technologies). Gene expression levels of NPM1 and ABL1 were detected using specific assays on Demand (Life Technologies) following the manufacturer's instructions: ID: Hs02339479_g1 (exon 4-5) for NPM1 and ID: Hs00245445_m1 (exon 3-4) for ABL1. RT-qPCR reactions were performed in quadruplicate for NPM1 and in duplicate for ABL1. NPM1 transcript levels were quantified relative to endogenous ABL1 and expressed as 2 2DDCt [17] . Universal Human Reference RNA (Stratagene, La Jolla, CA, USA) was used as calibrator in all experiments. A threshold value of 0.1 was used throughout the study.
Statistical analysis
Inter-group differences were analyzed by non parametric tests using first analysis of variance (ANOVA)
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Results and Discussion
One hundred forty five patients with MDS/AML (60 males and 85 females; median age = 68 years, range 9-94) were included in the study (Table S1 ).
The mono-allelic NPM1 deletion was a very infrequent lesion in the ''5q-syndrome'' because it was not detected in 42/43 cases. It identified two molecular sub-groups, here named NPM1+/2 and NPM1+/+, since it was present in 38/84 (45%) cases with complex karyotypes and 5q-. Interestingly Lessard et al. [18] demonstrated loss of the 5q35 chromosome band in 30% of de novo and therapy related AML. NPM1 loss may have occurred as an early step in MDS/AML as it remained stably mono-allelic in 4 NPM1+/2 patients and did not develop in 6 NPM1+/+ over a median of 9 months follow-up (range: 2-156 months) ( Table 2) .
The NPM1 loss was not cryptic since it was absent in 18 patients with complex karyotypes without 5q- (Table S1 ). Chromosome 5q breakpoints were distributed over a wide chromosomal area within genomic regions which extended beyond the isolated 5q deletion breakpoints. In NPM1+/2 patients telomeric breakpoints clustered between NPM1 and FGFR4 (approximately 5.7 megabases) in 4/16 cases and included subtelomeric sequences in 12 (75%) ( Figure 1A ,B,C, and Table S1 ). Centromeric breakpoints involved chromosome bands from q11.2 to q14.1 in more than 50% and were proximal to RP11-80K5 ( Figure 1A ,B,C, and Table S1 ). Notably in cases with isolated 5q deletions centromeric breakpoints always fell distally to RP11-80K5 ( Figure 1A and Table S1 ). Exon 12 mutations were not found in this study indicating that monoallelic NPM1 deletion and heterozygous mutation can not occur at the same time ( Figure 1D and Table S1 ). Furthermore, the NPM1 deletion corresponded to reduced NPM1 expression in MDS/AML cells which was significantly lower in NPM1+/2 cases than in the NPM1+/+ (P,0.001) and normal controls (P,0.001) (Figure 2) . Notably, NPM1 is a multifunctional protein which regulates ribosome biogenesis, TP53 protein activity and stability, ARF protein stability and localization, and DNA integrity [1, 19, 20] . In keeping with evidence from murine models [21] , in which NPM1 loss induced morphological signs of MDS, favored c-MYC lymphomagenesis and underlay chromosomal instability, chromosome rearrangements constituting complex karyotypes were significantly different in NPM1+/2 and NPM1+/+ patients. In NPM1+/+ structural chromosome rearrangements (translocations; deletions; insertions; inversions) were significantly more frequent (median 3, range 0-7 vs median 1.5, range 0-5; P = 0.013) ( Table S2 ) but in the NPM1+/2 group gross chromosomal changes (markers i.e. derivative chromosomes unclassified by karyotyping, rings, and double minutes) were significantly more common (median 3, range 0-9 vs median 0, range 0-6; P,0.001) ( Table S2) . Aneuploidy was present in 47/64 NPM1+/+ patients (73%) and in 38/38 NPM1+/2 patients (100%) (P,0.001). Significantly more monosomies were found in the NPM1+/2 subgroup (median 2, range 0-8 vs median 1, range 0-6; (Table S2) , with the most frequent, monosomy 7, being detected in 18/38 (47%) of NPM1+/2 and in 11/64 (17%) of NPM1+/+ (P = 0.002).
Since NPM1 is related to TP53 [19, 21223] , a master gene of chromosome stability that is frequently involved in MDS/AML with complex karyotype [24] , 57 cases from this series were investigated ( Table 3 and TableS1). Univariate analysis on TP53 and chromosome rearrangements showed a significant association between the number of monosomies and TP53 deletion and/or mutation (median 2 range 028 vs median 0 range 023; P = 0.006) ( Table S3) . However, both NPM1 and TP53 gene status maintained significant association with monosomies in a multivariate analysis (P = 0.014 and P = 0.013, respectively) (Poisson regression model), suggesting each gene plays an independent role, but may interact synergistically, in determining chromosomal abnormalities.
NPM1 loss was not associated with copy number variations of 14 genes other than TP53 that are putatively involved in the complex regulatory network of genetic stability. Gains and losses of clones containing BUB1A, ATR, FBW7, c-MYC, CDKN2A-2B, PTEN, CHEK1, ATM, MDM2, BRCA2, RB1, BUB1B, BRCA, CHEK2 were equally distributed in NPM1+/+ and NPM1+/2 cases (Figure 3) , suggesting that whatever roles these genes play in MDS/AML with complex karyotypes, they are independent of the NPM1 deletion.
In conclusion these findings prove that haploinsufficiency of the NPM1 gene, is present in more than 40% of patients with high risk MDS/AML characterised by chromosome 5q-and complex karyotypes. NPM1 haploinsufficiency and mutation appear to exert very different effects (Figure 4) as patients with NPM1 mutated-AML have normal karyotype, rare TP53 involvement, good prognosis if FLT3-ITD mutations are absent, and a predominance of females [2, 25, 26] . NPM1 haploinsufficiency was not linked to female gender (Table S4) . It significantly reduced NPM1 expression and, in synergy but independently of TP53 deletion and/or mutation, was associated with a strong tendency to perturb chromosomal stability. Consequently NPM1 gene status appears to indicate diverse genetic backgrounds in two different myeloid leukemias. 
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